Traws Pharma (TRAW) Income from Continuing Operations (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Income from Continuing Operations of 7212000.0 for Q1 2026, down 32.72% year-over-year from 10719367.61 in Q1 2025, and up 3.23% quarter-over-quarter from 7453000.0 in Q4 2025.
Traws Pharma (TRAW) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Income from Continuing Operations for 15 consecutive years, with 7212000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 32.72% year-over-year to 7212000.0; the TTM figure through Mar 2026 stood at 20166000.0 (up 86.27% YoY), while the FY2025 annual figure was 57641000.0, up 67.84% from the prior year.
- Income from Continuing Operations climbed to 7212000.0 in Q1 2026 per TRAW's latest filing, from 7453000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1274000.0 in Q2 2025 and bottomed at 175868000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 22504519.37 across 5 years, with a median of 5434000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 2575.66% — and 2025, when it soared 98.97%.
- Traws Pharma's Income from Continuing Operations stood at 175868000.0 in 2022, then surged by 97.45% to 4483000.0 in 2023, then tumbled by 77.92% to 7976000.0 in 2024, then advanced by 6.56% to 7453000.0 in 2025, then grew by 3.23% to 7212000.0 in 2026.
- Business Quant data shows TRAW's Income from Continuing Operations at 7212000.0 in Q1 2026, 7453000.0 in Q4 2025, and 4227000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | -3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.21 Mn |
| Dec 31, 2025 | -7.45 Mn |
| Sep 30, 2025 | -4.23 Mn |
| Jun 30, 2025 | -1.27 Mn |
| Mar 31, 2025 | -5.43 Mn |
| Dec 31, 2024 | -7.98 Mn |
| Sep 30, 2024 | -10.14 Mn |
| Jun 30, 2024 | -123.35 Mn |
| Mar 31, 2024 | -5.43 Mn |
| Dec 31, 2023 | -4.48 Mn |
| Sep 30, 2023 | -5.09 Mn |
| Jun 30, 2023 | -4.61 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -175.87 Mn |
| Sep 30, 2022 | -5.64 Mn |
| Jun 30, 2022 | -4.12 Mn |
| Mar 31, 2022 | -4.14 Mn |
| Dec 31, 2021 | -177.62 Mn |
| Sep 30, 2021 | -3.99 Mn |
| Jun 30, 2021 | -4.65 Mn |